Sealing of decellularized and recellularized artificial organ grafts

Abstract

To provide a reinforced decellularized and recellularized artificial organ graft by providing a method for sealing the decellularized and recellularized artificial organ graft.SOLUTION: A method of reducing the porosity of an outer fibrous layer of a decellularized mammalian organ or tissue or portion thereof, the method comprising contacting an exterior surface of a mammalian organ or tissue or portion thereof comprising a vascular tree and cells with a composition comprising at least one agent in an amount to form a coating on the exterior surface, wherein: Wherein the coating is effective to increase the retention of fluid in the organ or tissue relative to fluid introduced into the corresponding organ or tissue or portion thereof prior to exposure to the composition, and decellularizing the coated mammalian organ or tissue or portion thereof by perfusion decellularization.SELECTED DRAWING: None

Description

[Background technology]

[0001] The major categories of connective tissue are connective tissue proper, supportive tissue, and fluid tissue. Loose connective tissue proper includes adipose tissue, loose connective tissue, and reticular tissue. These hold organs and other tissues in place and, in the case of adipose tissue, serve to separate and store energy reserves. Adipose tissue lacks extracellular matrix, while matrix is ​​the most abundant feature of loose tissue. Dense connective tissue proper is more fibrous and may be regular, with fibers oriented parallel, as in ligaments and tendons, or irregular, with fibers oriented in various directions. Organ capsules (collagen type) contain dense irregular connective tissue. Dense connective tissue is reinforced by bundles of fibers that provide tensile strength, elasticity, and protection. When physicians encounter damaged donor organ surfaces during transplantation, they may treat bleeding by applying commercially available bioglues, fibrin sealants, hemostatic sponges, and other solutions, such as Surgefoam or Tisseal. Additionally, bleeding from liver injuries, whether caused by preoperative or intraoperative trauma, can be treated with gelatin gelfoam, oxidized cellulose, microfibrillar collagen, thrombin, thrombin with gelatin, or fibrin sealant. Summary of the Invention

[0002] The present disclosure provides a bioengineered decellularized organ or tissue, or portion thereof, that has been modified, e.g., coated to provide a seal, to provide a reinforced (reinforced) outer layer (an outer fibrous layer comprising an outer extracellular matrix having a composition that is at least 50% non-fibrillar collagen, in one embodiment, as opposed to parenchyma having more fibrillar collagen than non-fibrillar collagen) similar to or reinforced relative to the outer fibrous layer of the native organ or tissue in characteristics such as strength, extensibility, resilience, abrasion resistance, elastic modulus, and / or porosity. In one embodiment, the modified outer layer has increased strength, extensibility, resilience, abrasion resistance, elastic modulus, and / or reduced porosity relative to the outer fibrous layer of the corresponding native organ or tissue. The present disclosure also provides a bioengineered recellularized organ or tissue, or portion thereof, that has been modified to have a reinforced outer layer having similar or enhanced characteristics relative to the outer fibrous layer of the native organ or tissue. A bioengineered decellularized or recellularized organ or tissue or portion thereof is contacted with a biocompatible composition, e.g., an aqueous liquid, powder, or gel composition, which has one or more agents that, when coated on the surface of the organ or tissue or portion thereof, seal the exterior surface and, if present, any edges of the portion, such that aqueous fluids exogenously introduced and / or circulated within the vasculature of the organ or tissue or portion thereof are retained within the organ or tissue or portion thereof to a greater extent, e.g., at least 5%, 10%, or more, than when introduced and / or circulated within an organ or tissue or portion not contacted with the corresponding composition.In one embodiment, pressures, e.g., 5 to 10 mmHg (0.67 to 1.33 kPa), 10 to 22 mmHg (1.33 to 2.93 kPa), 20 to 40 mmHg (2.67 to 5.33 kPa), 50 to 60 mmHg (6.67 to 8.00 kPa), 60 to 100 mmHg (8.00 to 13.3 kPa), 100 to 150 mmHg (13.3 to 20.0 kPa) or more, are used to compare fluid retention. The modified outer surface resists fluid movement across the outer surface to a greater extent than an unmodified outer surface. Thus, the pressure applied to the fluid can be physiological pressure or a greater pressure, including, but not limited to, 5%, 7%, 10%, 20%, 50%, or 100% or more above the inherent pressure. For example, if the physiological pressure in the native liver is approximately 8 to 12 mmHg (1.07 to 1.60 kPa), then fluid introduced into a liver having a reinforced (stiffened) outer layer subjected to a pressure of at least 8 to 12 mmHg (1.07 to 1.60 kPa), e.g., at least 14 to 18 mmHg (1.87 to 2.40 kPa), will be retained within the liver to a greater extent than a liver without a corresponding reinforced outer layer. The physiological pressure for portal vein delivery of fluid to the liver is approximately 6 to 10 mmHg (0.80 to 1.33 kPa). The physiological pressure for delivery of fluid to the lungs is approximately 12 to 14 mmHg (1.60 to 1.87 kPa). Physiological pressures for arterial flow are about 80 to 120 mmHg (10.7 to 16.0 kPa), and physiological pressures for venous supply are about 8 to 14 mmHg (1.07 to 1.87 kPa). Thus, the reinforced outer layer of an organ will have a higher fluid retention capacity than a corresponding unreinforced outer layer of the organ, at least at physiological pressures and even at pressures higher than physiological pressures. In one embodiment, the introduced aqueous liquid forms less droplets on the dry outer surface of the organ after contact with the composition compared to the dry outer surface of the organ not contacted with the composition. In one embodiment, the introduced aqueous liquid leaks less (e.g., in volume) from the organ after contact with the composition relative to the organ not contacted with the composition, e.g., over time.In one embodiment, the composition is a gel, and the agent therein causes molecules on the exterior surface (outer surface) to crosslink, directly or indirectly, to one another. In one embodiment, crosslinking occurs as a result of a change in pH or temperature. In one embodiment, the agent is a light-activated crosslinker, e.g., UV light is used to initiate crosslinking. In one embodiment, the composition includes a polymer, e.g., a natural polymer, including a biocompatible composition or protein, that is crosslinked to molecules on the exterior surface of an organ or tissue or portion thereof, and optionally to other polymer molecules. In one embodiment, the polymer includes collagen, e.g., mammalian collagen, e.g., human or porcine collagen, including, but not limited to, porcine dermal collagen or gelatin derived therefrom, optionally excluding bovine collagen. The collagen can be of any molecular weight, e.g., 100 to 10,000 Da, 10,000 to 100,000 Da, or 100 to 500 kDa. In one embodiment, the composition comprises an enzyme such as a transferase, e.g., transglutaminase; a hydrolase, e.g., a peptidase; an oxidoreductase, e.g., isyl oxidase, tyrosinase, laccase, or peroxidase; or a hydroxylase, e.g., prill hydroxylase. In one embodiment, the composition may comprise an agent that reduces adhesion formation when the modified (coated) organ or tissue, or portion thereof, is transplanted. In one embodiment, the agent that reduces adhesion formation, e.g., laminin or collagen IV, may be applied after the organ or tissue, or portion thereof, is coated with the composition. In one embodiment, the agent that reduces adhesion formation, e.g., comprises polypropylene, provides a smooth surface. In one embodiment, the composition comprises a hydrophilic polymer. In one embodiment, the composition comprises a hydrophobic polymer. In one embodiment, the modification alters the mechanical properties of the outer fiber layer, which may be measured, for example, by ball burst, tensile strength, tear test, and / or fluid leakage.

[0003] Thus, a method is provided for reducing the porosity (e.g., fluid efflux therefrom) of the outer fibrous layer of a decellularized mammalian organ or tissue or portion thereof. The method may enable the development of a tissue or organ or portion thereof that can sustain higher pressures without fluid loss through the outer organ surface. The method includes providing a decellularized extracellular matrix of a mammalian organ or tissue or portion thereof, the decellularized extracellular matrix comprising an outer surface comprising a decellularized extracellular matrix and a decellularized extracellular matrix vascular tree, the decellularized extracellular matrix retaining most, but not all, of a fluid introduced into the decellularized extracellular matrix vascular tree of the organ or tissue or portion thereof. At least one outer surface is exposed to or contacted ex vivo with a composition comprising at least one agent in an amount that forms on the outer surface of the decellularized extracellular matrix of the mammalian organ or tissue or portion thereof a biocompatible coating effective to increase the retention of fluid introduced into the decellularized organ or tissue or portion thereof. [Brief explanation of the drawings]

[0004] [Figure 1] 1 shows a coating of a gelatin-based material cross-linked onto the surface of the liver extracellular matrix to seal and reinforce the surface, said material being able to cover the surface area non-uniformly. [Figure 2] The crosslinked material is shown to be stretchable and flexible on the surface of the extracellular matrix, indicating that the reinforced material has sufficient mechanical properties to be handled by operators during cultivation, delivery, implantation, and treatment. [Figure 3] 1 shows a typical coating of a reinforcing / strengthening composition on the surface of an excised pig liver. The entire liver surface is covered with a thin layer of the composition to seal and strengthen the capsule. The figure shows that the composition adheres to the liver surface after crosslinking and is able to bend and stretch along with the surface of the outer capsule. [Figure 4]1 shows a decellularized liver graft perfused with DI water at approximately 350 mL / min that exhibited leakage through the surface of the capsule, as evidenced by the formation of droplets of DI water on the surface of the capsule. [Figure 5] A decellularized liver graft with a strengthened / sealed surface treated with a UV-crosslinked gelatin material is shown, which is perfused with DI water at approximately 350 mL / min without leakage of fluid through the outer surface. [Figure 6] Polymer-coated and uncoated decellularized porcine livers (coated, decellularized, and recellularized with human endothelial cells) were subjected to an ex vivo blood loop at a constant flow rate of 350 mL / min, following the native portal vein flow. During the ex vivo blood loop, the liver grafts remained patent with a glucose consumption rate of over 80 mg / h. The coated grafts (with a benzophenone-based polymer that crosslinks upon exposure to UV light) exhibited reduced fluid movement through the outer capsule compared with uncoated grafts. These livers were decellularized and recellularized with human endothelial cells to allow for patency assessment and verification of effective organ coverage. [Figure 7] Polymer-coated and uncoated recellularized porcine kidneys (decellularized, coated, and recellularized) were transplanted into pigs through direct anastomosis of the renal artery and vein. After reperfusion, the coated grafts exhibited reduced fluid movement across their outer surface compared to uncoated kidneys. [Figure 8] Average leak rates (mL / min at 15 mmHg (2.00 kPa)) for decellularized, coated, and uncoated porcine liver grafts. Leak rates are calculated at a pressure of 15 mmHg (2.00 kPa) using a capped container and a standard PBS solution, which has a lower viscosity than blood. Coated decellularized livers showed a significant decrease in leak rate compared to uncoated decellularized grafts. A polymer coating was applied to freshly isolated livers prior to decellularization. The coating was robust and remained attached to the exterior surface throughout the decellularization process. DETAILED DESCRIPTION OF THE INVENTION

[0005] The boundaries and outer surfaces (sometimes referred to as capsules) of organs or tissues play important roles that may be compromised after decellularization. For example, the integrity of the organ's boundaries or surfaces may be reduced during the decellularization process, e.g., due to the removal of cells near the outer surface or a lack of inner cells, which reduces the bulk properties of the organ or tissue. This can lead to decellularized organ or tissue grafts being susceptible to fluid penetration (leakage) during perfusion, having reduced mechanical strength or flexibility, being prone to cracking, or having impaired handling characteristics. For example, it is easy to rupture an unmodified decellularized organ or tissue. To be physiologically compatible, an artificial organ graft should have an outer surface that can support the internal flow of blood within the vessels without leakage to the outside. Thus, even if the outer surface of a decellularized organ remains macroscopically intact or substantially intact, particularly if subjected to perfusion decellularization, removal of the outermost cell layer may lead to at least some leakage to the outside if fluid is introduced into the decellularized vasculature. The present disclosure provides an outer surface of an artificial organ or tissue graft that has resilient handling and placement characteristics, for example, conducive to successful implantation. In one embodiment, this can be achieved by strengthening and / or sealing the outside of the graft by depositing an additional chemical layer or by crosslinking, e.g., with a linker, molecules on or added to the cell surface that can strengthen the graft, such as by crosslinking the outer layer of extracellular matrix. Thus, the present disclosure provides methods for reinforcing, strengthening, and / or sealing decellularized and recellularized artificial organ grafts.

[0006] In one embodiment, strengthening the exterior of a bioengineered organ graft can be achieved by coating the decellularized organ graft with a substance (compound) capable of sealing the exterior. The substance can be in the form of a powder, liquid, or gel. The coated substance can provide crosslinking. The substance can be applied to the entire exterior surface or to portions of the exterior surface that are not expected to have integrity. Once applied to the organ or tissue or portion thereof, the layer of coated substance acts as a physical barrier, with or without further reaction, thereby sealing the organ or tissue or portion thereof against leakage and / or strengthening the organ or tissue or portion thereof, e.g., liver lobes, heart valves, lung lobes, left ventricle, right ventricle, renal pole, etc., to improve handling characteristics. Once applied, the organ or tissue or portion thereof is sufficiently robust that it has a range of bending and extension to accommodate the shape of the graft / organ, e.g., once recellularized. The deposited layer remains attached to the surface of the implant during subsequent handling, including, for example, the culture / manufacturing period, shipping period, and / or post-implantation. The applied compound (agent) and the resulting layer are biocompatible, allowing implantation without causing adverse effects. This may include modifications that will prevent, inhibit, or reduce adhesion formation after implantation. The applied material may also include molecules that prevent adhesion formation on the surface of the implant.

[0007] In one embodiment, the film-forming substance can be gelatin or a gelatin-like substance, such as one that is compatible with the species of the organ to which it is applied, that is initially flowable but then hardens and adheres once deposited on the surface of the implant. Flowable substances can include, but are not limited to, gelatin, agar, or carrageenan. In one embodiment, the substance can have properties that allow it to adhere to the surface of the implant by cross-linking with collagen on the surface of the implant. Additional catalytic cross-linking agents can include, but are not limited to, transglutaminase.

[0008] Other additives include, but are not limited to, polymers such as polyvinylpyrrolidone, photopolyvinylpyrrolidone, PEG, antibodies, amino acids, or proteins such as type I collagen, type II collagen, type III collagen, laminin, RGD, type IV collagen, etc.

[0009] The flowable film-forming material may include one or more photoreactive crosslinkers and / or a second component that crosslinks onto the surface of the implant, for example, upon UV exposure. In one embodiment, the photoreactive crosslinker, along with UV exposure, may induce covalent bonds between the solution components and the collagen surface of the implant, allowing the solution components to adhere to the surface of the implant, thereby strengthening and sealing the implant surface.

[0010] In one embodiment, the sprayable film-forming material may include one or more photoreactive crosslinkers and / or a second component that crosslinks onto the surface of the organ or tissue implant, for example, upon UV exposure. Curing of the crosslinker may be initiated by pH, chemicals, sound, heat, light, water, or laser. The material may be sprayed out of a spray nozzle or powered spray head, allowing for uniform application of the material onto the surface of the implant.

[0011] The organ graft can be immersed in a composition containing one or more photoreactive crosslinkers or a second component that crosslinks on the surface of the graft. The composition can also contain enzymes such as transferases, e.g., transglutaminase; hydrolases, e.g., peptidases; oxidoreductases, e.g., isyl oxidase, tyrosinase, laccase, or peroxidase; or hydroxylases, e.g., prolyl hydroxylase. The graft can be immersed in the composition and exposed to UV light to harden the surface, allowing crosslinking to occur. The pH of the composition can be altered to activate the enzyme action to crosslink the surface of the graft while the graft is immersed in the composition.

[0012] A powder material containing one or more enzyme- or photocrosslinkable polymers can be placed on the surface of the implant. The presence of moisture on the surface of the implant allows the powder to dissolve in solution, allowing a flowable liquid to coat the surface. The pH of the surface can trigger enzymatic action to crosslink the surface of the implant. Once the surface of the implant is coated, the surface can be exposed to UV radiation to crosslink the polymers to each other and to the surface of the implant.

[0013] General methods for producing decellularized and recellularized organs A solid organ refers to an organ with a "substantially closed" vasculature. A "substantially closed" vasculature in relation to an organ means that, during perfusion with a fluid, the majority of the fluid is contained within the solid organ and does not leak out of the solid organ, assuming major blood vessels are cannulated, ligated, or otherwise restricted. Despite having a "substantially closed" vasculature, many of the organs listed above define "inlet" and "outlet" vessels that are useful for the introduction and movement of fluid throughout the organ during perfusion. In addition, other types of vascularized organs or tissues, such as all or part of a joint (e.g., knee, shoulder, or hip), the anus, trachea, or spinal cord, can be perfusion decellularized. Furthermore, avascular tissues, such as cartilage or the cornea, can be decellularized when they are part of a larger vascularized structure, such as an entire leg.

[0014] Perfusion decellularization of the ECM of a tissue or organ provides intact EMC capable of imparting structural, biochemical, and mechanical properties to enable, for example, functional cell differentiation and maintenance. While perfusion decellularization of an organ or EMC of an organ is superior to immersion in preserving intact matrix with structural and biochemical cues, including intact vasculature, the compositions described herein may be used in tissues containing ECM tissues that are less susceptible to perfusion than immersion, for example, 2 cm 3 The present invention is effective for both perfusion and immersion of decellularized organs or tissues or portions thereof having a thickness greater than about 1 mm and / or a thickness greater than about 2 mm.

[0015] Perfused decellularized matrices of organs with a substantially closed vasculature are particularly useful because perfusion decellularization preserves an intact matrix and microenvironment, including intact blood vessels and microvasculature. The vasculature can be utilized to deliver cells, as well as nutrients and / or differentiation or maintenance factors, to cells outside the body. Cells and nutrients and / or other factors can be delivered by other means, such as injection, passive means, or a combination thereof. In one embodiment, cells of interest are perfused into the ECM of a perfused decellularized organ, allowing them to seed into the interstitial space or matrix outside of blood vessels. This includes active migration and / or homing of cells to native microstructures, such as the homing of beta cells to pancreatic islet structures within a pancreatic matrix. In one embodiment, cells of interest are perfused into the perfused decellularized ECM, followed by a second cell population, such as beta cells, followed by endothelial cells, while the endothelial cells remain within the blood vessels as in their native microenvironment. In another embodiment, two or more cell populations are mixed and perfused together. In another embodiment, two or more different cell populations are introduced sequentially by either perfusion, direct injection, or a combination of both. For example, hepatocytes are introduced into a perfused decellularized liver matrix by either perfusion or injection, followed by seeding with endothelial cells. In another embodiment, a perfused decellularized liver matrix is ​​seeded with fetal liver cells, including endothelial and epithelial cells. In another embodiment, fetal liver cells are seeded onto the matrix, followed by seeding with endothelial cells. In one embodiment, fetal lung cells, including a mixture of all lung cell types, including epithelial, endothelial, and interstitial lineages, are seeded by perfusion into the pulmonary vasculature and airways of a perfused decellularized lung to create a functional lung structure, such as a lung structure that results in further maturation of the isolated lung cells. In one embodiment, a perfused decellularized heart from a small animal, such as a rat, rabbit, mouse, guinea pig, or ferret, is perfused with partially differentiated human cardiomyocytes, human cardiac fibroblasts, human smooth muscle cells, and human endothelial cells to create a miniature beating human heart, e.g., for drug testing.

[0016] Cells can be introduced into a medium that supports cell growth, metabolism, and / or differentiation. Alternatively, after the cells have engrafted into the ECM, the medium is exchanged for one that supports cell growth, metabolism, and / or differentiation. Cultured cells can be present within the ECM at physiological cell density and in the presence of a medium that supports cell growth, metabolism, and / or differentiation, and / or the appropriate microenvironment within the ECM can allow for cell maintenance and / or functional differentiation.

[0017] Decellularization of organs or tissues Decellularization generally involves the following steps: stabilization of the solid organ or tissue, such as vascularized structures; decellularization of the solid organ or tissue; regeneration and / or neutralization of the solid organ or tissue; cleansing of the solid organ; degradation of DNA remaining on the organ; disinfection of the organ or tissue; and homeostasis of the organ.

[0018] The first step in decellularizing an organ vascularized structure or tissue is cannulation of the organ or tissue. The blood vessels, ducts, and / or cavities of the organ or tissue can be cannulated using methods and materials known in the art. The cannulated organ vascularized structure or tissue is then perfused with cell disruption medium. Perfusion through the organ can be multidirectional (e.g., antegrade and retrograde).

[0019] Langendorff perfusion of the heart is a technique commonly used in the art as physiological perfusion (also known as four-chamber working mode perfusion). See, e.g., Dehnert, The Isolated Perfused Warm-Blooded Heart According to Langendorff, In Methods in Experimental Physiology and Pharmacology: Biological Measurement Techniques V. Biomesstechnik-Verlag March GmbH, West Germany, 1988.

[0020] Briefly, in Langendorff perfusion, the aorta is cannulated and attached to a reservoir containing a physiological solution that allows the heart to function extracorporeally for a specified duration. Protocols for performing perfusion decellularization have been modified to perfuse a cell disruption medium delivered retrogradely down the aorta at a constant flow rate, delivered, for example, by an infusion pump, roller pump, or by a constant hydrostatic pump. In both instances, the aortic valve is forced closed, and the perfusion fluid travels into the coronary ostia (thereby perfusing the entire ventricular mass of the heart in the antegrade direction) and then flows through the coronary sinus into the right atrium. For working-mode perfusion, a second cannula is connected to the left atrium, and perfusion is changed to a retrograde direction.

[0021] In one embodiment, the physiological solution comprises phosphate-buffered saline (PBS). In one embodiment, the physiological solution is a physiologically compatible buffer, for example, supplemented with a nutritional supplement (e.g., glucose). For example, in the heart, the physiological solution can be a modified Krebs-Henseleit buffer containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO, 1.2 mM KHPO, 25 mM NaHCO, 11 mM glucose, 1.75 mM CaCl, 2.0 mM pyruvate-HCl, and 5 U / L inulin, gassed with 95% O, 5% CO, or a Krebs buffer containing 118 mM NaCl, 4.7 mM KCl, 25 mM NaHCO, 1.2 mM MgSO, 2 mM CaCl. The heart can be perfused with glucose (e.g., about 11 mM) as the sole substrate or in combination with about 1 or 1.2 mM palmitate. For the kidney, the physiological solution can be KPS-1® Kidney Perfusion Solution. For the liver, the physiological solution can be Krebs-Henseleit buffer containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO, 1.2 mM KHPO, 26 mM NaHCO, 8 mM glucose, 1.25 mM CaCl, supplemented with 2% BSA.

[0022] Methods for perfusing other organs or tissues are known in the art. For example, the following references describe perfusion of the lungs, liver, kidneys, brain, and limbs: Van Putte et al., Ann. Thorac. Surg., 74(3):893 (2002); den Butter et al., Transpl. Int., 8:466 (1995); Firth et al., Clin. Sci. (Lond.), 77(6):657 (1989); Mazzetti et al., Brain Res., 999(1):81 (2004); Wagner et al., J. Artif. Organs, 6(3):183 (2003).

[0023] One or more cell disruption media can be used to decellularize organs or tissues. Cell disruption media typically contain at least one surfactant, such as, but not limited to, SDS, PEG, CHAPS, or Triton X. The cell disruption medium may contain water, making the medium osmotically incompatible with cells. Alternatively, the cell disruption medium may contain a buffer (e.g., PBS) to make the medium osmotically compatible with cells. The cell disruption medium may also contain enzymes, such as, but not limited to, one or more collagenases, one or more dispases, one or more DNases, or proteases such as trypsin. In some instances, the cell disruption medium may also, or instead, contain one or more enzyme inhibitors (e.g., protease inhibitors, nuclease inhibitors, and / or collagenase inhibitors).

[0024] In some embodiments, a cannulated organ or tissue can be perfused sequentially with two different cell disruption media. For example, the first cell disruption media can contain an anionic surfactant such as SDS, and the second cell disruption media can contain an ionic surfactant such as Triton X. After perfusion with at least one cell disruption medium, the cannulated organ or tissue can be perfused with, for example, a wash solution and / or a solution containing one or more enzymes, such as the enzymes disclosed herein. Changing the direction of perfusion (e.g., forward and reverse) can aid in the decellularization of the entire organ or tissue. Decellularization generally decellularizes organs from the inside out, resulting in minimal damage to the ECM. The organ or tissue can be decellularized at an appropriate temperature between 4°C and 40°C. Depending on the size and weight of the organ or tissue and the concentration of the surfactant in the cell disruption medium, the organ or tissue is typically perfused with cell disruption medium for about 0.05 to about 5 hours per gram of solid organ or tissue (generally greater than 50 g), or about 2 to about 12 hours per gram of solid tissue or organ tissue (generally less than 50 g). Including irrigation, the organ may be perfused for up to about 0.75 to about 10 hours per gram of solid organ or tissue (generally greater than 50 g), or about 12 to 72 hours per gram of tissue (generally less than 50 g). Decellularization time, limited by the total mass range, depends on the vascularity and cell density of the organ or tissue. Therefore, the above time ranges and masses are provided as general guidance. Perfusion is typically adjusted to physiological conditions, including pulsatile flow, rate, and pressure.

[0025] A decellularized organ or tissue contains all or most of the extracellular matrix (ECM) components of the organ or tissue, including the extracellular matrix (EMC) components of the vascular tree. The EMC components may include some or all of the following, which may remain organized into defined structures such as basement membranes: fibronectin, fibrin, laminin, elastin, members of the collagen family (e.g., collagens I, III, and IV), ECM-associated growth proteins including growth factors and cytokines, glycosaminoglycans, ground substance, reticular fibers, and thrombospondin. Successful decellularization is defined as the absence of detectable myofilaments, endothelial cells, smooth muscle cells, and nuclei in tissue sections using standard histological staining procedures, or the removal of 97% or more of detectable DNA as measured by fluorescence analysis. Remaining cellular debris may be removed from the decellularized organ or tissue.

[0026] The morphology and structure of the ECM are maintained during and after the decellularization process. As used herein, "morphology" refers to the overall shape of the organ or tissue of the ECM, while "structure" as used herein refers to the outer surfaces, inner surfaces, and the ECM between them.

[0027] The morphology and structure of the ECM can be examined visually and / or histologically. For example, the basement membrane on the exterior surface of a solid organ or within the blood vessels of an organ or tissue should not be removed or significantly damaged due to perfusion decellularization. Furthermore, the fibrils of the ECM should be similar to or not significantly altered from the fibrils of the non-decellularized organ or tissue.

[0028] One or more compounds may be applied to or onto a decellularized organ or tissue, for example, to protect the decellularized organ or prepare it for recellularization and / or to support or stimulate cells during the recellularization process. Such compounds include, but are not limited to, one or more growth factors (e.g., VEGF-1, DKK-1, FGF, BMP-1, BMP-4, SDF-1, IGF, and HGF), immunomodulators (e.g., cytokines, glucocorticoids, IL2R antagonists, leukotriene antagonists), and / or factors that modify the coagulation cascade (e.g., aspirin, heparin-binding proteins, and heparin). Additionally, the decellularized organ or tissue may be further treated, for example, by irradiation (e.g., UV, gamma) to reduce or eliminate the presence of various microorganisms remaining on or within the decellularized organ or tissue.

[0029] Organ or tissue recellularization The decellularized organ or tissue is contacted with a population of cells, either differentiated (mature or primary), stem cells, or partially differentiated cells. Thus, these cells may be totipotent, pluripotent, or multipotent; naive or primed; or single-lineage cells. The cells may be undifferentiated, partially differentiated, or fully differentiated, including cells of fetal origin. The cells may include progenitor cells, precursor cells, or cells of "adult" origin, including umbilical cord and fetal stem cells. Cells useful in the matrices of the present invention include embryonic stem cells (as defined by the National Institutes of Health (NIH); see, for example, the glossary on the world wide web at stemcells.nih.gov) and iPS cells.

[0030] Examples of cells that can be used for organ or tissue recellularization include, but are not limited to, embryonic stem cells, umbilical cord blood cells, tissue-derived stem or progenitor cells, bone marrow-derived stem or progenitor cells, blood-derived stem or progenitor cells, mesenchymal stem cells (MSCs), skeletal muscle-derived cells, multipotent adult progenitor cells (MAPCs), or iPS cells. Additional cells that can be used can include cardiac stem cells (CSCs), multipotent adult cardiac-derived stem cells, cardiac fibroblasts, cardiac microvasculature endothelial cells, aortic endothelial cells, coronary artery endothelial cells, microvasculature endothelial cells, venous endothelial cells, arterial endothelial cells, smooth muscle cells, cardiomyocytes, hepatocytes, beta cells, keratinocytes, Purkinje fibers, neurons, bile duct endothelial cells, islet cells, lung cells, Clara cells, brush border cells, or podocytes. Bone marrow-derived stem cells such as bone marrow mononuclear cells (BM-MNC), endothelial or vascular stem or progenitor cells, and peripheral blood-derived stem cells such as endothelial progenitor cells (EPC) can also be used as cells.

[0031] The number of cells introduced into or onto the perfused decellularized scaffold can depend on both the organ (e.g., which organ, organ size, and weight) or tissue and the type and developmental stage of the recellularized cells. Different types of cells may have different tendencies regarding the population density they reach. Similarly, different organs or tissues can be cellularized at different densities. In examples, a decellularized organ or tissue can be "seeded" with at least about 1,000 (e.g., at least 10,000, 100,000, 1,000,000, 10,000,000, or 100,000,000) cells, or can have about 1,000 cells / mg tissue (wet weight, e.g., before decellularization) to about 10,000,000 cells / mg tissue (wet weight) attached thereto.

[0032] Cells can be introduced ("seeded") into a decellularized organ or tissue by injection into one or more locations. Furthermore, more than one type of cell can be introduced into a decellularized organ or tissue. For example, a group of differentiated cell types can be injected into multiple locations in a decellularized organ or tissue, or different cell types can be injected into different parts of a decellularized organ or tissue. Alternatively, or in addition to injection, cells or mixtures of cells can be introduced by perfusion into a cannulated decellularized organ or tissue. For example, cells can be perfused into a decellularized organ using a perfusion medium that can then be exchanged for an expansion and / or differentiation medium to induce cell growth and / or differentiation. Location-specific differentiation can be achieved by placing cells in various locations in the organ, for example, regions of the heart such as the atria, ventricles, or nodes.

[0033] During recellularization, the organ or tissue is maintained under conditions that allow at least some of the cells to grow and / or differentiate within or on the decellularized organ or tissue. These conditions include, but are not limited to, appropriate temperature and / or pressure, electrical and / or mechanical activity, force, appropriate O2 and / or CO2 levels, appropriate humidity, and sterile or near-sterile conditions. During recellularization, the decellularized organ or tissue and the recellularized cells attached thereto are maintained in a suitable environment. For example, the cells may require nutritional supplements (e.g., nutrients and / or a carbon source such as glucose), exogenous hormones or growth factors, and / or a specific pH.

[0034] The cells can be allogeneic to the decellularized organ or tissue (e.g., a human decellularized organ or tissue seeded with human cells), or the cells can be xenogeneic to the decellularized organ or tissue (e.g., a porcine decellularized organ or tissue seeded with human cells). As used herein, "allogeneic" refers to cells taken from the same species (e.g., related or unrelated individuals) as the organ or tissue is derived from, while "xenogeneic" as used herein refers to cells taken from a different species than the organ or tissue is derived from.

[0035] Stem or progenitor media may contain various components, including, for example, KODMEM medium (Knockout Dulbecco's Modified Eagle's Medium), DMEM, Ham's F-12 medium, FBS (fetal bovine serum), FGF2 (fibroblast growth factor 2), KSR, or hLIF (human leukemia inhibitory factor). Cell differentiation media may also contain supplements such as L-glutamine, NEAA (non-essential amino acids), P / S (penicillin / streptomycin), N2, B27, and beta-mercaptoethanol. It is anticipated that additional factors may be added to the cell differentiation medium, including, but not limited to, fibronectin, laminin, heparin, heparin sulfate, retinoic acid, members of the epidermal growth factor family (EGFs), members of the fibroblast growth factor family (FGFs) including FGF2, FGF7, FGF8, and / or FGF10, members of the platelet-derived growth factor family (PDGFs), transforming growth factor (TGF) / bone morphogenetic protein (BMP) / growth differentiation factor (DGF) factor family antagonists, including, but not limited to, noggin, follistatin, chordin, gremlin, cerberus / DNA family proteins, ventropin, high-capacity activin, and amnionless, or variants or functional fragments thereof. TGF / BMP / GDF antagonists may also be added in the form of TGF / BMP / GDF receptor Fc chimeras. Other factors that may be added include, but are not limited to, molecules capable of activating or inactivating signaling through the Notch receptor family, including the Delta-like and Jagged family of proteins, or variants or functional fragments thereof, as well as inhibitors of Notch processing or cleavage. Other growth factors may include members of the insulin-like growth factor family (IGF), insulin, the wingless-related (WNT) factor family, and the Hedgehog factor family, or variants or functional fragments thereof. Additional factors may be added to promote the proliferation and survival of mesendodermal stem / progenitor cells, endodermal stem / progenitor cells, mesodermal stem / progenitor cells, or definitive endoderm stem / progenitor cells, as well as the survival and differentiation of derivatives of these progenitor cells.

[0036] In one embodiment, the perfused decellularized matrix is ​​combined with iPS or ES cells differentiated using the embryoid body (EB) method. Human iPS cell lines reprogrammed by transfection with transcription factors (OCT4, SOX2, NANOG, and LIN28, Oct3 / 4, Sox2, Klf4, and c-Myc, or Oct3 / 4, Sox2, and Klf4), such as lentivirus-mediated transfection, are used. Fetal or neonatal iPS clones can also be used. Human ES cell lines can also be used. iPS and ES cells are cultured at 19,500 cells / cm in 6-well culture plates (Numc) in DMDM / F12 culture medium supplemented with 20% knockout serum replacement (Invitrogen), 0.1 mmol / L non-essential amino acids, 1 mmol / L L-glutamine, and 0.1 mmol / L β-mercaptoethanol (Sigma). 2 The cells can be maintained on irradiated mouse embryonic fibroblasts (MEFs) at a density of 10 ng / mL. The medium can be further supplemented with 10 ng / mL zebrafish basic fibroblast growth factor for iPS cells and 4 ng / mL human recombinant basic fibroblast growth factor (Invitrogen) for hES cells. iPS and ES cell lines can also be maintained in a medium containing 15% fetal calf serum (FCS; Sigma-Aldrich), 0.1 μmol / L 2-mercaptoethanol (2ME), and 1,000 units / mL erythrocyte sedimentation medium. The cells were maintained on gelatinized 100-mm dishes in DMEM (Sigma-Aldrich) containing LIF (Chemicon International). For differentiation, the cells were treated with 0.25% trypsin / ethylenediaminetetraacetic acid (GIBCO) and plated at 3 × 10 cells per well on gelatinized 6-well plates in α-minimal essential medium (GIBCO) supplemented with 10% FCS and 0.05 μmol / L 2ME. 4 The cells may be transferred at a concentration of 1000 cells / well.

[0037] Colonies can be detached from the culture plate by incubation in 1 mg / mL dispase (Gibco) solution for 8 to 15 minutes at 37°C and placed in suspension culture in ultra-low attachment plates for, e.g., 4 days. During suspension culture, the medium is changed on the first day and then cultured for another 3 days without medium changes. EBs are then plated onto 0.1% gelatin-coated culture plates or into perfused decellularized EMC at, e.g., a concentration of 50 to 100 EBs per well, and cultured in differentiation medium (e.g., changed daily).

[0038] In some instances, organs or tissues produced by the methods described herein are transplanted into a patient. In these cases, the cells used to recellularize the decellularized organ or tissue can be harvested from the patient, such that the cells are "autologous" to the patient. Patient-derived cells can be harvested, for example, from blood, bone marrow, tissue, or organs at different life stages (e.g., prenatal, neonatal, or perinatal, adolescent, or adult) using methods known in the art. Alternatively, the cells used to recellularize the decellularized organ or tissue can be syngeneic to the patient (i.e., from an identical twin), or the cells can be human lymphocyte antigen (HLA)-matched cells, for example, from a blood relative or an unrelated HLA-matched donor, or the cells can be allogeneic to the patient, for example, from an HLA-mismatched donor.

[0039] Regardless of the source of the cells (e.g., autologous or not), the decellularized solid organ can be autologous, allogeneic, or xenogeneic to the patient. Cell growth can be monitored during recellularization. For example, the number of cells on or in an organ or tissue can be assessed by taking samples at one or more time points during recellularization. Furthermore, the amount of differentiation the cells have undergone can be monitored by determining whether various markers are present on a cell or group of cells. Markers associated with different cell types and different stages of differentiation of those cell types are known in the art and can be readily detected using antibodies and standard immunoassays. See, e.g., Chapters 3 and 11 of *Current Protocols in Immunology*, 2005, Coligan et al., Eds., John Wiley & Sons. Nucleic acid analysis, as well as morphological and / or histological evaluation, can be used to monitor recellularization.

[0040] Exemplary Embodiments In one embodiment, organ surface reinforcement can be performed prior to the decellularization process. A reinforcing material can be deposited on the surface of the harvested organ to reinforce and seal the exterior of the organ. After deposition of the reinforcing material, the organ is subjected to the decellularization process, during which the exterior of the decellularized organ remains reinforced.

[0041] In one embodiment, reinforcement of the organ surface can be performed after the decellularization process and before recellularization. A reinforcement material can be deposited on the surface of the decellularized organ to reinforce or seal the exterior of the decellularized graft. After deposition of the reinforcement material, the graft can be seeded and cultured while the surface remains reinforced.

[0042] In one embodiment, reinforcement of the organ surface can be performed after the recellularization process. A reinforcement material can be deposited on the surface of the recellularized graft to reinforce and seal the exterior of the recellularized graft. After deposition of the reinforcement material, the graft can be cultured while the surface remains reinforced.

[0043] In one embodiment, organ surface reinforcement can be performed prior to implantation of the graft for treatment. A reinforcement substance can be deposited on the surface of the recellularized graft to reinforce and seal the exterior of the recellularized graft after delivery and prior to implantation. A bioengineered recellularized organ can be surface treated with the reinforcement substance at the implantation site.

[0044] In one embodiment, reinforcement of the organ surface can be performed before decellularization of the graft, and optionally after recellularization, e.g., before implantation. In one embodiment, reinforcement of the organ surface may be performed prior to decellularization, and optionally also prior to recellularization, of the graft.

[0045] In one embodiment, the flowable reinforcing material may be deposited onto the graft using methods such as, but not limited to, spraying, brushing / swabbing, or other methods of coating the organ, such as by dipping the organ in the material.

[0046] In one embodiment, the reinforcing material can be attached to the implant surface by crosslinking the material with the surface of the implant, for example, collagen on the surface of the implant. Crosslinking can be accomplished by catalytic agents such as, but not limited to, transglutaminase and other catalysts. Light-induced crosslinking can be assisted by the addition of a photocrosslinker to create a bond between the implant surface and the additive. Photocrosslinkers can be used to crosslink the existing surface of the organ. Additives include, but are not limited to, polymers, amino acids, and certain proteins.

[0047] Thus, the compositions disclosed herein can coat the entire surface of the implant. The coating can be applied prior to bleeding or oozing (leaking). In addition to creating a barrier, the composition can have hemostatic properties or be antithrombogenic. The coating can reduce surface porosity through mechanisms such as cross-linking, or the coating can create an adherent barrier coating with reduced porosity on the outer covering.

[0048] Polymer hydrogels may be formed using bifunctional monomers or cross-linkable polymers, optionally with a photoinitiator or cross-linking agent. In one embodiment, the coating is formed using polyvinylpyrrolidone (PVP) applied to the exterior surface of the organ and UV light. In one embodiment, the coating is formed using polyethylene glycol (PEG) applied to the exterior surface of the organ and UV light. In one embodiment, the coating is formed using agar applied to the exterior surface of the organ and UV light. In one embodiment, the coating is formed using gelatin applied to the exterior surface of the organ and UV light. In one embodiment, the coating is formed using collagen applied to the exterior surface of the organ and UV light.

[0049] In one embodiment, the applied composition can be a powder, such as collagen powder, to which a catalyst, such as a transferase, hydrolase, or oxidoreductase, has been added, which will activate on the surface and crosslink the collagen powder to the surface. For example, 5% (by weight) porcine dermal gelatin is prepared by warming water to 45°C and adding the gelatin powder while stirring the solution. 5% (by weight) active GS (transglutaminase) is added to the solution while stirring at 45°C. The pH is then titrated to 6.5-7 by adding 1N hydrochloric acid. Once the pH is within range, the solution is applied to the surface of the implant by swabbing or pouring. As the solution cools, it will undergo a phase change to a gel and then begin to crosslink due to the pH change. The setting time ranges from 1 to 4 hours as the solution cools, hardens, and crosslinks onto the implant.

[0050] In one embodiment, the composition applied is a liquid solution, such as a liquid solution containing a photoreactive cross-linking agent (such as photoactive polyvinylpyrrolidone, photopolyvinylpyrrolidone, benzophono, etc.) that is activated, for example, by UV light exposure, to cross-link the collagen-containing surface of the implant. In one embodiment, the composition applied is a gel, such as a liquid solution containing a gelatin-like component (such as gelatin, agar, carrageenan, etc.) that undergoes a phase change to a gel once applied onto the surface of the implant. The phase change allows the coating to remain on the implant and, in one embodiment, is the result of temperature, pH change, sound, chemicals, or water.

[0051] The resulting reinforced organ may have properties similar to or improved relative to the native organ. For example, the organ with the applied coating may have mechanical properties, such as mechanical strength, similar to or improved relative to the native organ. Mechanical properties may be measured using mechanical tests such as ball burst (ASTM D6797-15), pantothenia (ASTM D1938-19), or tensile strength (ASTM D5034-09). The organ with the applied coating may have structural or hemodynamic mechanical properties similar to or improved relative to the native organ, as measured by, for example, leak testing or fluid movement across the outer surface under a defined flow, which may be physiological.

[0052] In one embodiment, the applied composition can be a polymer with hydrophobic properties, such as a photoreactive polymer, thereby providing a hydrophobic surface that inhibits adhesions. In one embodiment, the applied composition can include a material that provides a hydrophilic coating that is both hydrophilic and non-adhesive. In one embodiment, the applied composition can be a modified protein such as laminin or a basement membrane substrate such as collagen IV that enhances the non-adhesive properties of the coating.

[0053] In one embodiment, the non-adherent component may be added after the coating is applied. In one embodiment, an ex vivo method is provided for reducing the porosity of the outer fibrous layer of a decellularized mammalian organ or tissue or portion thereof, the method comprising: removing an outer surface comprising a decellularized extracellular matrix, e.g., an 8 cm 2 organ or tissue, and the outer surface comprising a decellularized extracellular matrix vascular tree. 3The method includes providing a decellularized extracellular matrix of a larger mammalian organ or tissue or portion thereof, the decellularized extracellular matrix retaining most, but not all, of a fluid introduced therein, and exposing the exterior surface of the decellularized extracellular matrix of the mammalian organ or tissue or portion thereof to a composition comprising at least one agent in an amount that forms a biocompatible coating on the exterior surface of the decellularized extracellular matrix of the mammalian organ or tissue or portion thereof, the exterior surface including the decellularized extracellular matrix and the decellularized extracellular matrix vascular tree that has not been exposed to the corresponding composition. In one embodiment, the mammal is a pig, dog, cat, horse, goat, cow, sheep, or human. In one embodiment, the organ is a liver, heart, spleen, pancreas, bladder, kidney, small intestine, large intestine, stomach, bone, brain, or lung. In one embodiment, the composition comprises a powder, a gel, or a liquid, such as a water-soluble liquid. In one embodiment, the amount of the composition increases the mechanical flexibility or strength of the decellularized extracellular matrix of the mammalian organ or tissue. In one embodiment, the method also includes introducing cells into a duct, cavity, or one or more blood vessels of the decellularized organ or tissue. In one embodiment, the cells are introduced before exposing the exterior surface to the composition. In one embodiment, the cells are introduced after exposing the exterior surface to the composition. In one embodiment, the composition includes an agent that reduces adhesion formation. In one embodiment, the method further includes contacting the exterior surface with a composition including an agent that reduces adhesion formation. In one embodiment, the agent includes polypropylene. In one embodiment, the agent includes laminin, basement membrane matrix, or collagen IV. In one embodiment, the composition is sprayed onto the exterior surface. In one embodiment, the organ or tissue is immersed in the composition. In one embodiment, the exposure results in crosslinking of molecules on the exterior surface. In one embodiment, the agent is an enzyme, such as, for example, a transferase, hydrolase, oxidoreductase, or transglutaminase. In one embodiment, the crosslinked molecules include collagen. In one embodiment, the composition includes a photocrosslinking agent. In one embodiment, the exterior surface is exposed to the composition and the crosslinking agent.In one embodiment, the photocrosslinker comprises a polymer. In one embodiment, the composition comprises polyvinylpyrrolidone or photopolyvinylpyrrolidone. In one embodiment, the composition comprises poly(ethylene), poly(ethylene oxide), poly(vinyl alcohol), copolymers of maleic anhydride and / or phthalic anhydride with styrene, and some polymers derived from cinnamic acid. In one embodiment, the composition comprises benzophenone. In one embodiment, the composition comprises one or more amino acids. In one embodiment, the composition comprises type I collagen, type II collagen, type III collagen, laminin, RGD, or type IV collagen. In one embodiment, the agent comprises a bifunctional crosslinker. In one embodiment, the composition comprises gelatin, agar, or carrageenan. In one embodiment, the composition comprises collagen. Further provided are products made by this method.

[0054] In one embodiment, the fluid retention of the coated decellularized organ or tissue or portion thereof is increased by at least 5%, 10%, 30%, 40%, 50%, 70% or more relative to a corresponding uncoated decellularized organ or tissue or portion thereof.

[0055] In one embodiment, the coated decellularized organ or tissue or portion thereof has a fluid loss of less than 15 mL / min, 12 mL / min, 10 mL / min, 7 mL / min, 5 mL / min, 2 mL / min when fluid is introduced at physiological pressure or up to twice physiological pressure, relative to a corresponding uncoated decellularized organ or tissue or portion thereof which may lose fluid at a rate greater than, for example, 15 mL / min.

[0056] In one embodiment, an ex vivo method for reducing the porosity of an exterior surface of a mammalian organ or tissue or portion thereof is provided. The method includes providing a mammalian organ or tissue or portion thereof, the organ or tissue or portion thereof including an exterior surface, a vascular tree, and cells, and exposing the exterior surface of the organ or tissue or portion thereof to a composition including at least one agent in an amount that forms a coating on the exterior surface effective to increase fluid retention within the organ or tissue relative to fluids introduced into the organ or tissue or portion thereof prior to exposure to the corresponding composition. In one embodiment, the mammalian organ or tissue or portion thereof has not been decellularized and recellularized. In one embodiment, the mammalian organ or tissue or portion thereof has been decellularized and recellularized. Products made by this method are also provided.

[0057] In one embodiment, the fluid retention in the coated organ or tissue or portion thereof is increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 70% or more relative to a corresponding uncoated organ or tissue or portion thereof.

[0058] In one embodiment, the coated organ or tissue or portion thereof has a fluid loss of less than 15 mL / min, 12 mL / min, 10 mL / min, 7 mL / min, 5 mL / min, 2 mL / min or 0 mL / min when fluid is introduced at physiological pressure or up to twice physiological pressure, whereas a corresponding uncoated organ or tissue or portion thereof loses fluid at a rate greater than, for example, 15 mL / min.

[0059] Thus, the method includes coating before decellularization, after decellularization, or before implantation, or any combination thereof. All publications, patents, and patent applications are incorporated herein by reference. While the invention has been described in the foregoing specification with respect to certain preferred embodiments, and numerous details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to further embodiments, and that some of the details described herein may be varied considerably without departing from the fundamental principles of the invention.

Claims

1. 1. A method of reducing the porosity of the outer fibrous layer of a decellularized mammalian organ or tissue or portion thereof, comprising: contacting an exterior surface of a mammalian organ or tissue or portion thereof, including a vascular tree and cells, with a composition comprising at least one agent in an amount sufficient to form a coating on the exterior surface, the coating having the effect of increasing fluid retention in the organ or tissue relative to fluids introduced into the corresponding organ or tissue or portion thereof prior to exposure to the composition; and decellularizing the coated mammalian organ or tissue or portion thereof by perfusion decellularization; Optionally, the mammal is a pig, cow, sheep, or human; and optionally, the organ is a liver, heart, spleen, pancreas, bladder, kidney, small intestine, large intestine, stomach, bone, brain, or lung; The composition comprises a photocrosslinker, polyvinylpyrrolidone, photopolyvinylpyrrolidone, poly(ethylene), poly(ethylene oxide), poly(vinyl alcohol), copolymers of maleic anhydride and / or phthalic anhydride with styrene, or polymers derived from cinnamic acid or benzophenone.

2. The method of claim 1 , wherein the composition is a powder, a gel, or a liquid.

3. 3. The method of claim 1 or 2, wherein the amount of the composition increases the mechanical flexibility or strength of the decellularized extracellular matrix of the mammalian organ or tissue.

4. 10. The method of claim 1, further comprising the step of introducing cells into a duct, cavity, or one or more blood vessels of the decellularized organ or tissue.

5. The method of claim 1 , wherein the composition comprises an agent that reduces adhesion formation.

6. 10. The method of claim 1, further comprising contacting the exterior surface with a composition comprising an agent that reduces adhesion formation, e.g., the agent comprises polypropylene, laminin, basement membrane matrix, or collagen IV, or an enzyme such as a transferase, hydrolase, oxidoreductase, or transglutaminase.

7. 10. The method of claim 1, wherein the composition is sprayed, brushed, or painted onto the exterior surface, or the organ or tissue is immersed in the composition.

8. 10. The method of claim 1, wherein the photocrosslinker comprises a polymer or the exterior surface is contacted with polyvinylpyrrolidone, photopolyvinylpyrrolidone, poly(ethylene), poly(ethylene oxide), poly(vinyl alcohol), copolymers of maleic anhydride or phthalic anhydride with styrene, or polymers derived from cinnamic acid or benzophenone.

9. 10. The method of claim 1, wherein the exterior surface is contacted with polyvinylpyrrolidone, photopolyvinylpyrrolidone, poly(ethylene), poly(ethylene oxide), poly(vinyl alcohol), copolymers of maleic anhydride or phthalic anhydride with styrene, or polymers derived from cinnamic acid or benzophenone.

10. 10. The method of claim 1, wherein the composition comprises one or more amino acids or collagen, including type I collagen, type II collagen, type III collagen, laminin, RGD, or type IV collagen, gelatin, agar, or carrageenan.

11. The method of claim 1 , wherein the at least one agent comprises a bifunctional crosslinker.

Images